The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
The once-high-flying firm has been beset by challenges since going public via a SPAC merger in 2021. Here’s the latest.
No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...
But what can customers of 23andMe themselves do to make sure their highly personal genetic data is protected? And should we ...
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
Since its founding in 2006, 23andMe has sold more than 12 million of its DNA kits, which use a saliva sample to extract DNA ...
PCMag on MSN1d
23andMe to Cut 40% of Its Staff Amid Grim FinancialsThe DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on ...
23andMe's woes were further exacerbated by a data breach last year, wherein hackers gained access to personal information of ...
23andMe Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, ...
Me announced on Monday it would cut approximately 40% of its workforce, impacting over 200 employees. The restructuring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback